Tango Therapeutics, Inc.
NASDAQ: TNGX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Malte Peters
- Employees
- 155
- Headquarters
- Boston, United States
- IPO year
- 2020
- Market cap
- $3.5B
- Website
- https://www.tangotx.com
Loading TNGX…
Loading profile data…Frequently asked questions about TNGX
What does Tango Therapeutics, Inc. (TNGX) do?
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancer...
Where does TNGX trade?
Tango Therapeutics, Inc. (TNGX) trades on the NASDAQ Global Market.
What sector is TNGX in?
Tango Therapeutics, Inc. (TNGX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tango Therapeutics, Inc.?
Malte Peters is the chief executive officer of Tango Therapeutics, Inc. (TNGX).
Where is Tango Therapeutics, Inc. headquartered?
Tango Therapeutics, Inc. is headquartered in United States.
Does TNGX pay a dividend?
Tango Therapeutics, Inc. (TNGX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TNGX go public?
Tango Therapeutics, Inc. (TNGX) completed its initial public offering in 2020.